Short Interest in Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Declines By 90.8%

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCYGet Free Report) was the target of a large drop in short interest during the month of October. As of October 31st, there was short interest totalling 34,300 shares, a drop of 90.8% from the October 15th total of 374,300 shares. Based on an average trading volume of 202,400 shares, the days-to-cover ratio is presently 0.2 days.

Chugai Pharmaceutical Stock Down 2.1 %

Chugai Pharmaceutical stock traded down $0.50 during mid-day trading on Tuesday, reaching $23.55. 44,857 shares of the company traded hands, compared to its average volume of 128,588. The firm’s 50 day moving average price is $23.77 and its 200 day moving average price is $20.37. Chugai Pharmaceutical has a 52-week low of $14.52 and a 52-week high of $26.00.

Chugai Pharmaceutical Company Profile

(Get Free Report)

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.

Featured Articles

Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.